{
  "name" : "dacemirror.sci-hub.se_journal-article_cb0771f301c5ff40cecd77d256489387_mohsen2019.pdf",
  "metadata" : {
    "source" : "CRF",
    "title" : "Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Ef cacy of an Instantly Formulated Cancer Nano-Vaccine",
    "authors" : [ "Brian J. Czerniecki", "Mona O. Mohsen", "Monique Vogel", "Carsten Riether", "Silvia Salatino", "Ariane C. Gomes", "Christiane Ruedl", "Thomas M. Kundig", "Daniel E. Speiser", "Martin F. Bachmann" ],
    "emails" : [ "mona.mohsen@dbmr.unibe.ch;", "monamona20@icloud.com" ],
    "sections" : [ {
      "heading" : null,
      "text" : "ORIGINAL RESEARCH published: 15 May 2019\ndoi: 10.3389/ mmu.2019.01015\nFrontiers in Immunology | www.frontiersin.org 1 May 2019 | Volume 10 | Article 1015\nEdited by: Brian J. Czerniecki,\nMof tt Cancer Center, United States\nReviewed by: Catherine J. Wu,\nDana Farber Cancer Institute, United States\nWilliam Gillanders, Washington University in St. Louis,\nUnited States\n*Correspondence: Mona O. Mohsen\nmona.mohsen@dbmr.unibe.ch; monamona20@icloud.com\nSpecialty section: This article was submitted to\nCancer Immunity and Immunotherapy, a section of the journal\nFrontiers in Immunology\nReceived: 10 January 2019 Accepted: 23 April 2019 Published: 15 May 2019\nCitation: Mohsen MO, Vogel M, Riether C,\nMuller J, Salatino S, Ternette N, Gomes AC, Cabral-Miranda G, El-Turabi A, Ruedl C, Kundig TM, Dermime S, Knuth A, Speiser DE and\nBachmann MF (2019) Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Ef cacy of an Instantly Formulated Cancer\nNano-Vaccine. Front. Immunol. 10:1015.\ndoi: 10.3389/ mmu.2019.01015\nTargeting Mutated Plus Germline Epitopes Confers Pre-clinical Ef cacy of an Instantly Formulated Cancer Nano-Vaccine Mona O. Mohsen 1,2,3*, Monique Vogel 2, Carsten Riether 4, Julius Muller 1, Silvia Salatino 5, Nicola Ternette 1, Ariane C. Gomes 1, Gustavo Cabral-Miranda 2, Aadil El-Turabi 1, Christiane Ruedl 6, Thomas M. Kundig 7, Said Dermime 3, Alexander Knuth 3, Daniel E. Speiser 8 and Martin F. Bachmann 1,2\n1 Nuf eld Department of Medicine, Jenner Institute, University of Oxford, Oxford, United Kingdom,2 Department of BioMedical Research, Immunology RIA, University Hospital ofBern, Bern, Switzerland,3 National Center for Cancer Care & Research, Doha, Qatar,4 Department of Medical Oncology, University Hospital of Bern, Bern, Switzerland,5 Wellcome Centre for Human Genetics, University of Oxford, Oxford, United Kingdom, 6 Division of Molecular Genetics and Cell Biology, Nanyang Technological University, Singapore, Singapore,7 Department of Dermatology, University of Zurich, Zurich, Switzerland,8 Department of Oncology, University of Lausanne, Lausanne,Switzerland\nPersonalized cancer vaccines hold promises for future cancer therapy. Targeting neoantigens is perceived as more bene cial compared to germline, non-mutated antigens. However, it is a practical challenge to identify and vaccinate patients with neoantigens. Here we asked whether two neoantigens are suf cient, and whether the addition of germline antigens would enhance the therapeutic ef cacy. We developed and used a personalized cancer nano-vaccine platform basedon virus-like particles loaded with toll-like receptor ligands. We generated threesets of multi-target vaccines (MTV) to immunize against the aggressive B16F10 murine melanoma: one set based on germline epitopes (GL-MTV) identi ed by immunopeptidomics, another set based on mutated epitopes (Mutated-MTV) predicted by whole exomesequencing and a last set combines both germline and mutated epitopes (Mix-MTV).Our results demonstrate that both germline and mutated epitopes induced protectionbut the best therapeutic effect was achieved with the combination of both. Our platform is based on Cu-free click chemistry used for peptide-VLP coupling, thus enabling bedside production of a personalized cancer vaccine, ready for clinical translation.\nKeywords: virus-like particles, vaccine, personalized, me lanoma, neoantigen, mutated, germline\nINTRODUCTION\nMelanoma is the most aggressive type of skin cancer mostly due to its high metastatic potentials (1). The complexity of melanoma phenotype a ects its responsiveness tovari us therapies. Therefore, scientists emphasize the need for personalized treatments, includi g vaccinations that target neoantigens representing the uniqueness of each patient’s tumor (2, 3). Neoantigens are considered attractive because T-cells speci c for these altered-self antigens are not expected to be attenuated by immune tolerance mechanisms as compared to T-cells speci c for conserved self-antigens (4 6). Given the facts that powerful tumor in ltrating T-cells recognize multiple tumor antigens (7),\nand that targeting of a single antigen allows tumors to relapse (8), it is desirable to target multiple antigens (3, 9, 10). However, identifying su cient numbers of neoantigens may be di cultfor many human tumors that often show low mutational burden such as prostate and pancreatic cancers (11 13). Targeting neoantigens by using synthetic long peptides (14), RNA-based vaccines (15), or DC-based vaccines (16) have so far only been done in patients with tumors of high mutational burden, essentially melanoma.\nWe have shown previously that VLPs derived from the bacteriophage Qb loaded with A-type CpGs and coupled to MelanA/MART-1 peptide can be e ciently processed by murine and human DCs for MHC-I presentation and induced strong CD8C T-cell responses in HLA-A2 transgenic mice as well as in melanoma patients (17, 18). Recent research has also shown that CMP-001, a product that is also based on Qb-VLPs loaded with the same A-type CpGs induced tumor regressions in advanced melanoma patients treated by direct intra-tumoral injection, even though the VLPs used were not linked to tumor-speci c antigens. Three clinical trials for CMP-001 are currently ong ing (NCT02680184, NCT03084640, and NCT03618641).\nIn this study, we have utilized VLPs to build up a personalized multi-target vaccine based on identi ed germline and predicted mutated peptides coupled to TLR 9-ligand loaded VLPs by the non-toxic bio-orthogonal Cu-free click chemistry. The generated vaccine candidates induced e ective CD8C T-cell responses and the strategy can also be implemented for solid tumors with low mutational burdens as identi cation of germline epitopes with high a nity to MHC-I molecules is always feasible.\nMATERIALS AND METHODS\nProduction and Puri cation of Q b-VLPs Qb-VLPs expression and production was performed as previously described in detail in Kozlovska et al. (19), Cielens et al. (20), and Storni et al. (21).\nPackaging Q b-VLPs With B-Type CpGs B-type CpGs (500-TCC ATG ACG TTC CTG ATG CT-300) with phosphorothioate backbone was custome made by (IBA). Twenty mM HEPES (Sigma Aldrich) was used to solubilize Qb-VLPs and RNase A (Merck) was used to digest the naturally packaged RNA inside Qb-VLPs (1.2 mg/ml RNaseA/ 3 mg/ml Qb-VLPs) for 3 h at 37 C. The digestion was con rmed using 1% agarose gel and SYBR safe dye. Qb-VLPs was then repackaged with B-type CpGs (1.125mg/ 20mg Qb-VLPs) and packaging was also con rmed by using 1% agarose gel stained by SYBRsafe stain, while Qb-VLPs protein was detected by subsequent staining with coomassie blue.\nGeneration of Q b(CpGs)-p33 Vaccine Using SMPH Chemistry B-type CpGs were packaged in Qb-VLPs as described earlier and then derivatized for 1 h at RT using SMPH (Succinimidyl 6-((beta-maleimidopropionamido)hexanoate)) (Thermo Fisher Scienti c). Excess SMPH cross-linker was removed using Amicon centrifuge tubes of 100 kDa MWCO (SigmaAldrich). Modi ed p33 peptide derived from Lymphocytic\nChoriomeningitis Virus LCMV was synthesized by the addition of GGC amino acids (a.a.) at the C-terminus HKAVYNFATMGGC-NH2 (Pepscan BRESTO) to facilitate its coupling to SMPH cross-linker. The modi ed peptide was reconstituted in DMSO and added in 10-fold molar excess over Qb(CpGs)-VLPs monomer. The mixture was incubated for 1 h at RT and excess peptide was removed using Amicon centrifuge tubes. The coupling e ciency was tested by SDS-PAGE stained with coomassie blue and assessed by densitometric analysis of the SDS-PAGE by comparing Qb-VLP monomer bands to Qb-VLP monomer plus p33 after coupling.\nGeneration of Q b(CpGs)-p33 Vaccine and Multi-Target Vaccines Using DBCO (Cu-Free Click Chemistry) B-type CpGs were packaged in Qb-VLPs as described earlier and then derivatized for 30 min at RT using DBCO (dibenzocyclooctyne NHS ester) (Sigma-Aldrich). Excess DBCO cross-linker was removed using Amicon centrifuge tubes of 100 kDa MWCO (Sigma-Aldrich). Modi ed p33 peptide was synthesized by the addition of GGCK a.a. and an azide (N3) group at the C-terminus H-KAVYNFATMGGCK(N3)-NH2 (Pepscan BRESTO) to facilitate its coupling to DBCO crosslinker. The peptides for the multi-target vaccines (MTV) were synthesized by the addition of extra 4 a.a. using their anking protein sequence and an azide (N3) group at the C-terminus. The generation of multi-target vaccine was done for each peptide separately. The modi ed peptides were reconstituted in DMSO and added in 10-fold molar excess over Qb(CpGs)-VLPs monomer. The vaccine was incubated for 30 min at RT and excess peptide was removed using Amicon centrifuge tubes. The e ciency of the coupling was tested as explained in section Generation of Qb(CpGs)-p33 vaccine using SMPH chemistry.\nMice Wild type C57BL/6 mice were purchased from Harlan.Rag2 = mice on a C57BL/6 background were provided by Ochsenbein’ lab and bred in our pathogen-free animal facility. Allin vivo experiments used 8 12-week-old female. All animal procedures were performed in accordance with the Swiss Animals Act (455.109.1) (September 2008, 5th) of University of Bern.\nMeasuring p33 Speci c T-Cell Response With Tetramers P33 (H-KAVYNFATM-NH2) tetramers designed with H2-Db allele and APC or PE uorochrome (TCMetrix) was used to measure p33 speci c T-cells. WT C57BL/6 mice (8 12 weeks old; Harlan) were vaccinated s.c. once with 50mg Qb(CpGs)p33 vaccine coupled with SMPH or DBCO cross-linkers. Seven days later spleens were collected and smashed using 70mM cell strainer (Sigma-Aldrich). Cells were washed 1x with sterile PBS and RBCs were lysed using ACK lysis bu er. 1 106 cells were collected in 96-well V-bottom plate and stained with p33 tetramers (TCMetrix) followed by anti-CD8a (53 6.7, BD Biosciences) for ow cytometric analysis by FACSCanto and FlowJo Software.\nFrontiers in Immunology | www.frontiersin.org 2 May 2019 | Volume 10 | Article 1015\nIntra-cellular Cytokine Staining for IFN- g Intra-cellular cytokine staining was performed on spleens or TILs of vaccinated mice to measure IFN-g. 2 106 cells were collected from spleen or TIL and pulsed with 1mg of p33 peptide or with the mixture of germline peptides or mutated peptides or both according to the vaccine group for 6 h at 37 C with 1:1,000 Brefeldin A and Monensin (BD Biosciences). Cells were collected and washed 3x with sterile PBS/0.1% BSA. 1 106 cells were collected in 96-well V-bottom plate and stained with anti-CD8a (53 6.7, BD Biosciences). Cells were then xed with 100ml of the xation bu er (Thermo Fisher Scienti c) and permeabilized with 1x of the permeabilization bu er (Thermo Fisher Scienti c). Cells were stained with anti-IFN-g (XMG1.2, BD Biosciences) for ow cytometric analysis by FACSCanto and FlowJo Software.\nCFSE in vivo Cytotoxic Assay WT C57BL/6 mice (8 12 weeks old; Harlan) were vaccinated with a single s.c. injection of 50mg Qb(CpGs)-p33 vaccine coupled with SMPH cross-linker or DBCO cross-linker. Seven days later, target splenocytes from naïve WT C57BL/6 mice were collected and RBCs were lysed and divided into 2 groups. The 1st naïve splenocyte group was labeled with 2mM CFSE (Thermo Fisher Scienti c) and kept un-pulsed while the 2nd naïve splenocytes group was rst pulsed with 1mg p33 and then labeled with 10mM CFSE. The prepared target groups were mixed in 1:1 ratio and each previously vaccinated mouse receiv d 1 107 of un-pulsed CFSELow cells and 1 107 of pulsed CFSEHi cells intravenously. Four hours later the spleens of the vaccinated mice were collected and analyzed by ow cytometry for frequency of CFSELow and CFSEHi . Speci c lysis for each group was measured using the formula RatioD 100X(1 CFSEHi pulsed/CSFELow un-pulsed).\nImmunopeptidomics B16F10 melanoma cell line transfected with p33 peptide was provided by Ochsenbein’s lab and cultured in T-150 cm2 ask using Dulbecco’s modi ed Eagle’s medium (DMEM) with 10%FBS and 1% Streptomycin/Penicillin. Cells at 80% con uency were washed 2x with sterile PBS and collected with scrapers, centrifuged and freezed at 80 C. Cells were lysed using 5 ml lysis bu er (1% Igepal, 300 mM sodium chloride, 100 mM Tris, pH 8.0) supplemented with protease inhibitor cocktail (Roche) for 30 min on ice. Lysates were cleared by two centrifugation steps at 500 g for 10 min and then 20,000 g for 60 min. One mg of anti-mouse MHC class I antibody (ATCC HB-51) was bound and cross-linked to 1 ml Protein G beads (GE healthcare). Lysates were incubated with the antibody beads over night at4 C and washed subsequently with 50 mM Tris, pH 8.0 containing either 150, 450 mM, and no salt. Peptides were eluted with 5 ml 10% acetic acid and concentrated in a vacuum concentrator (Eppendorf). Peptides were then injected onto a 4.6 50 mm ProSwift RP-1S column on an Ultimate 3000 system (Thermo Fisher Scienti c). Peptides were separated from larger complex components by elution using a 500ml/ min ow rate over 10 min from 2 to 30% ACN in 0.1% TFA. Alternate fractions that did not contain the beta-2-microglobulin were pooled and two nal fractions were analyzed by nano-ultra performance\nliquid chromatography tandem mass spectrometry (nUPLCMS2) on a Fusion Lumos (Thermo Fisher Scienti c). Peptides were separated on a Ultimate 3000 RSLCnano system (Thermo Fisher Scienti c) using a PepMap C18 column, 2mm particle size, 75mm 50 cm (Thermo Fisher Scienti c) with a 1 h linear gradient of 3 25% bu er B (0.1% formic acid, 5% DMSO in acetonitrile) in bu er A (0.1% formic acid, 5% DMSO in water) at a ow rate of 250ml/ min. Peptides were introduced using an Easy-Spray source at 2000 V to a Fusion Lumos (Thermo Fisher Scienti c) at 305 C. Full MS spectra were recorded from 300 to 1,500 m/z in the Orbitrap at 120,000 resolution with an AGC target of 400,000. Precursor selection was performed using TopSpeed mode at a cycle time of 2 s. Peptide ions were isolated using an isolation width of 1.2 amu and trapped at a maximal injection time of 120 ms with an AGC target of 300,000. Higher-energy collisional dissociation (HCD) fragmentation was induced at an energy setting of 28 for peptides with a charge state of 2 4, while singly charged peptides were fragmented at an energy setting of 32 at lower priority. Fragments were analyzed in the Orbitrap at 30,000 resolution. Analysis of raw data was performed using Peaks 7.5 software (Bioinformatics Solutions). Sequence interpretation of MS2 spectra was carried out using databases containing all mus musculus UniProt database entries at a FDR of 1.4. Motif analysis of common a.a. in peptide sequences was performed using WebLogo 3.5 (weblogo.threeplusone.com). Peptide binding predictions were performed using NetMHCpan 4.0.\nWhole Exome Sequencing B16F10 melanoma cell line was cultured and collected as described earlier. DNA was isolated using Purelink genomic DNA mini kit according to manufacturer’s instructions (Thermo Fisher Scienti c), and gave a yield of 394 ng/ul. The qualityof the DNA yield was assessed by loading an aliquot on 2% agarose gel. A library was prepared using Agilent SureSelect XT, based on the cRNA-baits targeted capture. The Mouse All Exon kit captures 49.6 Mb region that covers 221,784 exons within 24,306 genes. Sequencing was performed using HiSeq 2,500 machine with paired end 2x 25 run, aiming 100 (raw data) exome coverage by FASTERIS.\nBioinformatics Analysis of Whole Exome Sequencing Sequenced reads from the B16F10 melanoma cell line sample were mapped to the Mus musculus reference genome assembly GRCm38 from NCBI using the software BWA-MEM (22) with default parameters. Supplementary alignments were removed and the resulting BAM le was sorted with SAMtools (23). Mapped reads were subsequently used as input for the variant calling software Platypus (version 0.8.1, specifying the option minFlank D0 ) (24) to identify SNPs and short indels (< 50 bp). The 74138 identi ed variants were annotated with standard R packages using GENCODE and further investigated with the Variant E ect Predictor Ensembl frame-work (VEP, releas 90) (25). Peptides were extracted using a sliding window from C/ 8AA to C/ 14AA around the mutation. HLA\nFrontiers in Immunology | www.frontiersin.org 3 May 2019 | Volume 10 | Article 1015\ntype prediction for H2-Db and H2-Kb alleles was performed using NetMHC4.0.\nIn vitro T-Cell Assay 1 106 B16F10 melanoma cells were injected into the ank of C57BL/6RAG2 = mice (8 12 weeks old). Twelve days later the growing tumors were collected and processed for transplantation into the ank of WT C57BL/6 mice (8 12 weeks old; Harlan) under anesthesia. The tumors were allowed to grow without any treatment for 14 days (set as the humane end point 1,000 mm3). Tumors were collected and digested by DNaseI (Boehringer) and collagenase D (Roche) in 5% FSC containing DMEM for 1 h at 37 C. Tumors were then smashed using 100mm cell strainer (Sigma-Aldrich) and washed 2x with PBS. Tumor-in ltrating lymphocytes (TILs) were separated using Ficoll-paque premium (GE Healthcare) by centrifugation for 30 min at RT at 1,800 rpm. TILs were collected and kept on ice. At the same time bone marrow derived dendritic cells (BMDCs) were prepared from naïve WT C57BL/6 mice (8 12 weeks old; Harlan). Brie y, bone marrow cells were cultured in RPMI supplemented with 10% FCS, glutamine, sodium pyruvate, penicillin, and streptomycin for 6 8d in the presence of granulocyte-macrophage colonystimulating factor containing X-63 cell supernatant. BMDCs were then pulsed with the selected peptides separately for 1 h at 37 C. The pulsed BMDCs were then washed 3x with DMEM medium and co-cultured with the collected TILs for 6 h at 37 C with (1:1,000) Brefeldin A and Monensin (BD Biosciences). ICS staining was carried out as described in section Intra-cellular cytokine staining for IFN-g.\nMeasuring Treg Peripheral blood from WT C57BL/6 mice (8 12 weeks old; Harlan) vaccinated with MTV was collected in heparin. RBCs were lysed with ACK lysing bu er (Thermo Fisher Scienti c) and cells were stained with anti-CD4 (RM4-5, eBioscience) and anti-CD25 mAb (CD25-4E3, BD Biosciences) for ow cytometric analysis by FACSCanto and FlowJo Software.\nTumor Experiments and Survival Rate 1 106 B16F10 melanoma cells were injected into the ank of C57BL/6RAG2 = mice (8 12 weeks old). Twelve days later the growing tumors were collected and processed for transplantation into the ank of WT C57BL/6 mice (8 12 weeks old; Harlan). Vaccination was carried 5 days later as described inTable 1.\nTumors were collected 14 days later as the control groups reached the humane end-point of 1,000 mm3. Tumor volume was measured using a caliper according to the formula VD (W W L)/2, where V is tumor volume, L is tumor length and W is tumor width. TILs were isolated as described earlier. TILs were stained with anti-CD8a (53 6.7, BD Biosciences), anti-IFNg (XMG1.2, BD Biosciences), anti-CD45 (30-F11, Biolegend), anti-Ly6G (1A8, Biolegend), and anti-Ly6C (HK1.4, Biolegend) for ow cytometric analysis by FACSCanto and FlowJo Software. Survival was evaluated using the same designated vaccines and the transplanted WT C57BL/6 mice (8 12 weeks old; Harlan) were vaccinated twice a week and tumor size was monitored daily and measured using a caliper.\n1 120 mg Qb(CpGs)-VLPs s.c.\n2 10 mg anti-CD25 (PC61, Biolegend) i.v.\n3 Germline multi-target vaccine (GL-MTV) 120 mg containing: 20 mg Qb(CpGs)-PMEL17 20 mg Qb(CpGs)-MTC-1 20 mg Qb(CpGs)-Calpastatin 20 mg Qb(CpGs)-ZFP518 20 mg Qb(CpGs)-TRP-2 20 mg Qb(CpGs)-Caveolin2\ns.c\n10 mg anti-CD25 (PC61, Biolegend) i.v.\n4 Mutated multi-target vaccine (Mutated-MTV) 120 mg containing: 60 mg Qb(CpGs)-Cpsf3l 60 mg Qb(CpGs)-Ki 8b\ns.c.\n10 mg anti-CD25 (PC61, Biolegend) i.v.\n5 Mix multi-target vaccine (Mix-MTV) 120 mg containing: 15 mg Qb(CpGs)PMEL17 15 mg Qb(CpGs) MTC-1 15 mg Qb(CpGs)-Calpastatin 15 mg Qb(CpGs)-ZFP518 15 mg Qb(CpGs)-TRP-2 15 mg Qb(CpGs)-Caveolin2 15 mg Qb(CpGs)-Cpsf3l 15 mg Qb(CpGs)-Ki 8b\ns.c.\n10 mg anti-CD25 (PC61, Biolegend) i.v.\nStatistics Data have been presented as mean SEM using GraphPad PRISM 7.0d. Comparison between the groups was performed by Student’st-test or one-way ANOVA. Tumor growth curves were analyzed by AUC and survival was analyzed by Log-rank (Mantel-Cox) test.P-values P< 0.0001; P< 0.001; P< 0.01; P< 0.05.\nRESULTS\nAlgorithm for the Generation of a Personalized Melanoma Vaccine Platform Based on VLPs We adapted the Qb-VLP/CpG platform for the generation of a personalized cancer vaccine in mice as illustrated inFigure 1. Using immunopeptidomics and whole exome sequencing we identi ed and predicted tumor-speci c germline and mutated CTL epitopes of the B16F10 melanoma cell line. The identi ed and predicted epitopes were then prioritized and validated by bioinformatics andin vitro experiments. We used bio-orthogonal copper (Cu)-free click chemistry; a key step in our platform to couple the selected peptides to CpG-loaded Qb-VLPs to form MTV. The vaccines were produced with germline epitopes, germline-multi target vaccine (GL-MTV) or mutated epitopes (Mutated-MTV) or a combination of both (Mix-MTV) in mice transplanted with aggressive B16F10 melanoma tumors.\nFrontiers in Immunology | www.frontiersin.org 4 May 2019 | Volume 10 | Article 1015\nFIGURE 1 | Algorithm for the generation of a personalized melanoma vaccine platform based on VLPs. First, tumor-speci c epitopes need to be identi ed in a systematic way. Here, immunopeptidomics approach has been used to identify potential tumor-speci c germline epitopes and whole exome sequencing to predict the mutated ones. In a second step, the identi ed and predicted epitopes should be prioritized and this was basically achieved by bioinformatics and stimulation of tumor-in ltrating cellsusing in vitro T-cell assay. Next, the selected epitopes are extended to 13 14 amino acids long peptides using their anking protein sequence for the goal oftargeting CD8C CTL. The extended peptides are then synthesized and coupledto CpG-loaded VLPs using Cu-free click chemistry. A mix-multi target VLP-based vaccine is proposed.\nBio-orthogonal Cu-Free Click Chemistry; an Ef cient Method for Coupling Antigens to VLPs to Enhance Their Immunogenicity For the development of VLP-based vaccines, we previously used SMPH cross-linker to couple the peptide of interest to VLPs (21, 26 28). Linking of cysteine on peptides to lysine on VLPs by SMPH has indeed proven reliable for development of VLPbasedvaccines. However, for the generation of a personalized cancer vaccine, the method may have several disadvantages, namely that epitope internal cysteine will also react with SMPH\non VLPs, causing their inactivation and non-reacted SMPH on VLPs is potentially toxic, requiring complex inactivation, and puri cation procedures after coupling. Therefore, this technique is not well-suited for rapid personalized vaccine production. For these reasons, we established a coupling method based on bio-orthogonal Cu-free click chemistry using a DBCO cross-linker (Figure 2A). This method is non-toxic and thus enables rapid and e cient coupling of regulatory compliant GMP produced VLPs and peptides that can potentially be done at patients’ bedside. We compared the e ciency of DBCO based Cu-free click chemistry to the standard SMPH-based method by coupling p33 peptide -as a model antigen- derived from LCMV to Qb-VLPs loaded with Btype CpGs. Cu-free click chemistry signi cantly enhanced the coupling of the model antigen to Qb-VLPs compared to SMPH when assessed by SDS-PAGE (Figure 2B) and densitometric analysis demonstrated enhanced peptide coupling by DBCO compared to SMPH (Figure 2C). In a next step, we compared the immunogenicity of the vaccines generated by the two coupling methodsin vivo. WT C57BL/6 mice were vaccinated once subcutaneously (s.c.) with Qb(CpGs)-p33 vaccine prepared with SMPH or Cu-free click chemistry method. Qb-VLPs were packaged with B-type CpGs for successful activation of DCs and cross-priming. Seven days later, spleens were collected and tested for p33 speci c CD8C T-cells by assessing the percentage of p33 tetramer binding and IFN-g production. Immunization of C57BL/6 mice with the Qb(CpGs)p33 vaccine based on Cu-free click chemistry resulted in signi cant increase in p33 speci c CD8C T-cells (p. 0.0012) (Figures 2D,G) as well as signi cant production of IFN-g (p. 0.0421) (Figure 2E) when compared to SMPH method. Lytic activity was also enhanced when assayedin vivo by performing CFSE cytotoxicity assay (Figures 2F,H). Thus, Cu-free click chemistry improves vaccine immunogenicity compared to the standard SMPH chemistry.\nIdenti cation and Prediction of CD8 C\nT-Cell Epitopes of B16F10 Melanoma Cells by Immunopeptidomics and Whole Exome Sequencing In a next step, we performed immunopeptidomics for B16F10 murine melanoma cell line to identify peptides naturally presented on MHC-I molecules. As expected, a large number of MHC-I-associated peptides was identi ed (Figures 3A,B). Next, the peptides were evaluated for a number of essential physical parameters including the length, MHC haplotype (H2-Db and/or H2-Kb) and a nity to MHC-I (high a nity ranking peptides) as summarized inTable 2. Using literature-based assessment of key characteristics such as being melanocyte-speci c or a candidate oncogene were also considered. Six peptides were selected from immunopeptidomics for the generation of GLMTV includes PMEL17, MTC-1, Calpastatin, ZFP518, TRP-2, and Caveoline2.\nAs for mutated peptides, Castle et al. have previously xploited the mutanome of B16F10 melanoma cell line\nand identi ed several non-synonymous point mutations\nFrontiers in Immunology | www.frontiersin.org 5 May 2019 | Volume 10 | Article 1015\nFIGURE 2 | Bio-orthogonal Cu-free click chemistry; an ef cient methodfor coupling antigens to VLPs to enhance their immunogenicity. (A) A sketch illustrating the coupling method using Bio-orthogonal Cu-free click chemistry (dibenzocyclooctyne NHS ester DBCO). Brie y, NHS ester reacts with Lys residues on VLPs and incorporates a cyclooctyne moiety which reacts with the azide labeled molecule forming a stable triazole linkage.(B) SDS-PAGE stained with coomassie blue showing the coupling ef ciency of p33 to Qb(CpGs)-VLP using SMPH cross-linker or DBCO cross-linker. Lane 1 protein marker, lane 2 Qb-VLP monomer, lane 3 Qb(CpGs)-VLP derivatized with SMPH cross-linker, lane 4 Qb(CpGs)-p33 vaccine using SMPH cross-linker, lane 5 Qb(CpGs)-VLP derivatized with DBCO cross-linker, lane 6 Qb(CpGs)-p33 vaccine using DBCO cross-linker. Each extra band in lanes 4 and 6 indicates a peptide binds to a Qb monomer. (C) Densitometric analysis of SDS-PAGE lanes 1, 4, and 6. (1) uncoupled Qb-VLP, total 180 monomers, (2) Qb(CpGs)-p33 vaccine using SMPH cross-linker, and (3) Qb(CpGs)-p33 vaccine using DBCO cross-linker. Notice the percentage of the coupled peptides to Qb-VLP monomers, total 180 monomers.(D) Percentage of CD8C TetramerC cells (means SEM) in the spleen of vaccinated groups: group 1) Qb(CpGs)-VLPs, group 2) Qb(CpGs)-p33 vaccine using SMPH cross-linker, and group 3) Qb(CpGs)-p33 vaccine using DBCO cross-linker.(E) Percentage of CD8C IFN-gC secreting cells (means SEM) in the spleen of vaccinated groups.(F) CFSE in vivo lytic activity in the spleen of vaccinated groups, using the formula 100X(1 CFSEHi pulsed/CSFELow un-pulsed). Statistical analysis by Studentst-test. (G) Representative FACS plots showing the percentage of CD8C TetramerC cells in the spleen of vaccinated groups.(H) Representative FACS histogram of CFSEin vivo lytic activity in the spleen of vaccinated groups. (n D 3) mice per group, one representative of 3 similar experiments is shown. *P < 0.05I **P < 0.01I ***P < 0.001I ****P < 0.0001.\nand tested> 50 peptidesin vitro (8). The most promising peptides with mutations in Kif18b and Cpsf3l genes were tested separatelyin vivo for their anti-tumor e ect. They used long synthetic peptides (27 a.a.) targeting both CD8C and CD4C cells. Based on these ndings we have carried out whole exome sequencing to con rm somatic point mutations in these two speci c genes in our B16F10 cell line. We identi ed several non-synonymous single nucleotide variants (SNVs), including a point-mutation in the 13th exon of the Kif18b gene a ecting the transcript ENSMUST00000021311 (Chr11:102,908,157; c.2367T> G; p.Lys739Asn) (Figure 3C), and in the 9th exon of the Cpsf3l gene a ecting both ENSMUST00000120794 (Chr4:155,886,970; c.1021G> A; p.Asp292Asn) and ENSMUST00000030901 (Chr4:155,886,970; c.1087G> A; p.Asp314Asn) isoforms (Figure 3D). Accordingly, mutated Kif18b and Cpsf3l peptides were selected for the generation of (Mutated-MTV). We have predicted the a nity of the selected two mutated peptides to H2-Db and H2-Kb allelesin silico as summarized inTable 3. Please note that we have only selected the best two mutated peptides from B16F10 melanoma model as the mutation burden in most of other cancers is low and therefore it is not always feasible to predict mutated peptides. In vitro Validation of Germline and Mutated Epitopes Identi ed by Immunopeptidomics and Predicted by Whole Exome Sequencing Tumor-in ltrating lymphocytes are highly enriched with tumor speci c T-cells and thus are the most relevant T-cell population in this regard (29). Therefore, we have used TILs to validate\nFrontiers in Immunology | www.frontiersin.org 6 May 2019 | Volume 10 | Article 1015\nFIGURE 3 | Identi cation and prediction of CD8C T-cell epitopes of B16F10 melanoma cells by immunopeptidomics and whole exome sequencing.(A) Length distribution of peptides identi ed by immunopeptidomics.(B) 8 and 9 mers motifs identi ed by immunopeptidomics.(C) Whole exome sequencing results showing a heterozygous SNV (marked in red and orange) in the 13th exon of gene Kif18b at position Chr11:102,908,157 (ENSMUST0000021311: c.2367T> G, p.Lys739Asn), causing a K> N missense mutation.(D) Whole exome sequencing results showing a heterozygous SNV (marked in orange and green) in the 9th exon of gene Cpsf3l at position Chr4:155,886,970 (ENSMUST00000120794: c.1021G> A, p.Asp292Asn and ENSMUST00000030901: c.1087G> A; p.Asp314Asn), causing a D> N missense mutation.\nthe natural immunogenicity of the six selected peptides from immunopeptidomics and the two mutated epitopes predicted by whole exome sequencing. The selected peptides were synthesized for this experiment as 8 or 9 a.a. to study their recognition by TILs. To this end, TILs were isolated from WT C57BL/6 bearing B16F10 melanoma tumors and cultivatedex vivowith IL-2 for 2 3 days. The used melanoma cell line has also been transfected with the model peptide p33 derived from LCMV which was used as a positive control. The activated TILs were then co-cultured with BMDCs pulsed separately with the selected peptides. P33 peptide was used as a positive internal control while actin peptide was used as a negative control due to expected strong immune tolerance. IFN-g production was then assessed by performing intra-cellular\nFrontiers in Immunology | www.frontiersin.org 7 May 2019 | Volume 10 | Article 1015\ncytokine staining (Figures 4A,B). The results indicated that the selected peptides were e ective at inducing signi cant IFN-g production by T-cells when compared to actin. There was no signi cant di erence between p33 and the selected germline or mutated peptides.\nMulti-Target VLP-Based Vaccine Using Cu-Free Click Chemistry Could Signi cantly Hinder the Progression of the Aggressive Transplanted B16F10 Tumor Displaying peptides on CpG-loaded VLPs represents a unique possibility to increase their immunogenicity for T-cells. Henc , Qb-VLPs were used as a sca old and packaged with B-type CpGs. The packaging was con rmed by agarose gel and the selected peptides were coupled to Qb-VLPs using Cu-free click chemistry. The vaccines were produced with germline epitopes (GL-MTV) identi ed by immunopeptidomics, mutated epitopes (MutatedMTV) predicted by whole exome sequencing or a combination of both (Mix-MTV). The aim of preparing these groups separately was to compare their overall immunogenicity. The developed\nvaccines were tested in WT C57BL/6 mice bearing the aggressive B16F10 melanoma tumors. We have adapted a challenging therapeutic murine melanoma model by transplanting 2 mm3 sized B16F10 tumor fragment into the ank of WT C57BL/6 mice and let it grow for 5 more daysin vivobefore vaccination started Figure 5A. In order to enhance the e cacy of the developed MTVs, they were combined with anti-CD25 mAb to deplete Tregs and facilitate CTLs in ltration. Anti-CD25 was chosen based on a number of preliminary data showing that anti PD-1 did not enhance the e cacy or immunogenicity of the developed multi-target VLP-based vaccines against B16F10 melanoma cell line, while anti-CD25 did (please note that Daclizumab, the anti-CD25 antibody used in humans, does not deplete Tregs in vivo). The transplanted WT C57BL/6 mice were vaccinated s.c. with the developed MTV in combination with low dose of anti-CD25, 3 times over 14 days as the control groups reached the ethical end point by day 14 (Figure 5B). The depletion of Tregs characterized by CD4C , CD25hi was assessed in the periphery of vaccinated mice on day 6 post tumor transplantation (Figures 5C,D). All three multi-target VLP-based vaccines could signi cantly hinder the progression of B16F10 melanoma tumor when assessing the tumor volume at day 14 in comparison to the groups vaccinated with Qb(CpGs)-VLP or anti-CD25 alone. However, anti-tumor protection was more e cient when vaccinating with Mix-MTV than with GL-MTV or MutatedMTV (Figures 5E,F). Furthermore, when assessing the growth curve of the aggressive B16F10 tumors over the 14 days, only Mix-MTV showed signi cant reduction in the tumor growth (p D 0.03). Treatment with anti- Qb(CpGs)-VLP or CD25 mAb alone did not show any anti-tumor protection (Figures 5G,H).\nFIGURE 4 | Validation of germline and mutated epitopes identi ed by immunopeptidomics and predicted by whole exome sequencing.(A) Percentage of CD8C IFN-gC secreting cells (means SEM) in duplicate, pre-gated on TILs. p33 peptide was used as apositive control and actin as a negative control. Statistical analysis by Student’s t-test in comparison with Actin ( ve control).(B) Representative FACS plots showing the percentage of CD8C IFN-gC secreting cells pre-gated on TILs and stimulated with Actin ( ve control), p33 (Cve control), ZFP518, Cpsf3l, PMEL17, and Kif18b peptides. One representative of 3 similar experiments is shown. *P < 0.05I **P < 0.01I ***P < 0.001I ****P < 0.0001.\nFrontiers in Immunology | www.frontiersin.org 8 May 2019 | Volume 10 | Article 1015\nFIGURE 5 | Multi-target VLP-based vaccine using Cu-free click chemistry could signi cantly hinder the progression of the aggressive transplanted B16F10 tumor.(A) A sketch of the challenging therapeutic murine melanoma model based on injecting 1 106 B16F10 melanoma cell line into the ank of C57BL/6RAG2 = mice. Twelve to thirteen days later the growing tumors are collected and processed for transplantation of 2 mm3 into the ank of C57BL/6 WT mice. (B) Vaccination scheme of ve groups: Qb(CpGs)-VLPs, anti-CD25, germline-multi target vaccine (GL-MTV), Mutated-MTV, and Mix-MTV GL-MTV.(C) Representative percentage of CD4C CD25Hi in the periphery of the groups vaccinated with Qb(CpGs)-VLPs, anti-CD25, and Mix-MTVCanti-CD25 on day 6 post-tumor transplantation.(D) Representative FACS plots showing the percentage of CD4C CD25Hi in periphery of the groups vaccinated with Qb(CpGs)-VLPs, anti-CD25, and Mix-MTVCanti-CD25 on day 6 post-tumor transplantation.(E) Photographic images of s.c. B16F10 tumors on day 14 post-tumor transplantation.(F) Tumor volume mm3 (means SEM) measured on day 14 post-tumor transplantation for the groups vaccinated with Qb(CpGs)-VLPs, anti-CD25, GL-MTV, Mutated-MTV and Mix-MTV, each dot represents a tumor. Statistical analysisby Student’s t-test. (G) Individual tumor growth curves of s.c. B16F10 melanoma of thedesignated groups. (H) Combined tumor growth curves of the designated groups, arrows indicate start of treatment. Statistical analysis by AUC. The groups of GL-MTV, Mutated-MTV, and Mix-MTL were combined with anti-CD25mAb in all experiments. (n D 5) mice per group, one representative of 3 similar experiments is shown. *P < 0.05I **P < 0.01I ***P < 0.001I ****P < 0.0001.\nMix Multi-Target VLP-Based Vaccine Increased CD8 C T-Cell In ltration Into B16F10 Tumor and Enhanced the Survival It is readily accepted that high-grade CD8C T-cell density in tumors is correlated with better prognosis and is an essential piece of evidence for e ective immune responses (7, 30). Based on that, we measured the total number of in ltrating CD8C T-cells in the tumors and calculated their density in each vaccinated group (by dividing the total number of CD8C Tcells in each tumor by its volume). Mix-MTV signi cantly increased CD8C T-cells density when compared to the groups vaccinated with Qb(CpGs)-VLPs (p. 0.0028), anti-CD25 (p. 0.0076), or Mutated-MTV (p. 0.01). The statistical di erence between Mix-MTV and GL-MTV was borderline signi cant (p. 0.06) (Figures 6A,C). When assessing the density of CD8C IFN-gC secreting cells in the tumors, the data showed that Mix-MTV group induced the strongest cytokine production which was superior to the groups vaccinated with GL-MTV or Mutated-MTV (Figure 6B). These results underline the e ectiveness of combining both germline and mutated epitopes in one vaccine when treating the aggressively growing B16F10 melanoma tumor. Whether the di erent multi-target VLP-based vaccines can extend the life-span of tumor-bearing mice was tested next. Tumors in control mice or mice treated with anti-CD25 mAb alone reached their ethically allowed maximal size of 1,000 mm3 within 13 16 days, underscoring the aggressiveness of the model used. Vaccination with the GL-MTV or MutatedMTV in combination with anti-CD25 mAb extended the mouse life-span by about 8 days while the Mix-MTV did so by about 16 days (Figure 6D). In fact, vaccination with the Mix-MTV reached protective levels of the vaccine based on p33 peptide, one of the strongest T-cell epitopes known in mice.\nFrontiers in Immunology | www.frontiersin.org 9 May 2019 | Volume 10 | Article 1015\nFIGURE 6 | Mix multi-target VLP-based vaccine increased CD8C T-cell in ltration into B16F10 tumor and enhanced the survival. (A) Density of CD8C T-cells (means SEM) in tumor, pre-gated on TILs in the groups vaccinated with Qb(CpGs)-VLPs, anti-CD25, GL-MTV, Mutated-MTV, and Mix-MTV. The density measured by dividing the total number of CD8C T-cells in each tumor by its volume.(B) Density of CD8C IFN-gC secreting cells (means SEM) in tumor, pre-gated on TILs in the vaccinated groups. Statistical analysis by one-way ANOVA.(C) Representative FACS plots showing the total number of CD8C T-cells in each tumor in the vaccinated groups. (D) Survival of mice in the vaccinated groups, mice were euthanized when the tumor reached 1,000 mm3. The arrows indicate vaccination time. Statistical analysis by log-rank test. The groups of GL-MTV, Mutated-MTV, and Mix-MTL were combined with anti-CD25mAb in all experiments. (n D 5) mice per group, one representative of 3 similar experiments is shown. *P < 0.05I **P < 0.01I ***P < 0.001I ****P < 0.0001.\nMix Multi-Target Vaccine Altered the Myeloid Composition of B16F10 Tumor We have studied next the e ect of the vaccination with the prepared multi-target vaccines on tumor myeloid immune cell composition. Speci cally, we have looked at both granulocytic and monocytic myeloid populations in TILs. There was an overall increase in the Ly6GC granulocytic population in the groups vaccinated with Mix-MTV and GL-MTV in comparison to the control groups Qb(CpGs)-VLPs or anti-CD25. However, the in ltration of Ly6GC granulocytes into the tumour was signi cantly higher in the group vaccinated with Mix-MTV when compared to the groups vaccinated with GL-MTV (p. 0.0331) or Mutated-MTV (p. 0.0015) (Figures 7A,C). The increase in the granulocyte population was accompanied by a decrease in monocytic population characterized by Ly6CC which is shown prominently in the group vaccinated with MixMTV (Figures 7B,C). The observed increase in granulocytic population and the decrease in monocytic one was inversely correlated with the tumor volume (p 0.0003) as shown in (Figure 7D) and is compatible with induction of a more protective environment (31, 32). DISCUSSION VLPs have shown to be a promising platform for the development of e ective vaccines. Such platforms signi cantly enhance the immunogenicity of tumor epitopes and help overcoming tolerance and anti-in ammatory milieus (33, 34). Indeed, it has been shown previously that a VLP-based vaccine can be utilized for active immunization against melanoma and vaccination against a single epitope resulted in strong CTL responses and exerted therapeutic pressure to the extent of provoking outgrowth of antigen escape variants in mice and humans (17, 18,35). Personalized cancer vaccines targeting the patient’s tumor speci c mutanome may have the potential to generate clinically e ective T-cell responses (14, 15). In previous studies, multitarget long peptides, or RNA-based vaccine have been used to induce CD8C (and CD4C) T-cell responses in melanoma\nFrontiers in Immunology | www.frontiersin.org 10 May 2019 | Volume 10 | Article 1015\nFIGURE 7 | Mix multi-target vaccine altered the myeloid composition of B16F10 tumor. (A) Percentage of Ly6GC cells (means SEM) in TILs, pre-gated on CD45C cells in the groups vaccinated with Qb(CpGs)-VLPs, anti-CD25, GL-MTV, Mutated-MTV, and Mix-MTV. (B) Percentage of Ly6CC cells (means SEM) in TILs, pre-gated on CD45C cells in the vaccinated groups. Statistical analysis by one-way ANOVA.(C) Representative FACS plots showing the percentage of Ly6GC and Ly6CC cells in TILs in the vaccinated groups.(D) Correlation between the ratio of the percentage of Ly6GC and Ly6CC cells over the tumor volume mm3 in the vaccinated groups. Statistical analysis by linear regression. The groups of GL-MTV, Mutated-MTV, and Mix-MTL were combined with anti-CD25mAb in all experiments. (n D 5) mice per group, one representative of 3 similar experimentsi shown. *P < 0.05I **P < 0.01I ***P < 0.001I ****P < 0.0001.\npatients. Interestingly, even though the vaccines were design d to induce CTL responses, they preferentially stimulated CD4C T-cells, reminiscent of the generally acknowledged di culties in mobilizing strong and broad CD8C T-cell responses by vaccination (14, 15, 36, 37). Nevertheless, these ndings support the concept that a multi-target vaccine covering a broader range of cancer antigens can control tumor progression and avoid outgrowth of antigen-escape variants.\nIn this study, a novel platform for the generation of a personalized VLP-based vaccine has been developed by combining both immunopeptidomics and whole exome sequencing techniques. Earlier versions of VLP-based vaccines using SMPH chemistry to couple antigens of interest to VLPs showed good e cacy. SMPH reacts with free Lysine on the VLP and free cysteine on the peptides. However, not only cysteinesof the linker but also cysteines within the target epitope may react with SMPH, resulting in the inactivation of cysteine-containing epitopes. In addition, non-reacted SMPH on VLPs may be toxic as it can react with cysteines in the body after injection of the vaccine. To overcome this problem and enable mixing and coupling of peptides with VLPs at bedside, a new coupling chemistry should be employed that leaves cysteines untouched and that will not react with anything in the host. To this end, bio-orthogonal Cu-free click chemistry has been implemented here for GMP-compatible production at bedside. The results show that DBCO is superior to SMPH cross-linker in terms of (1) coupling e ciency to Qb-VLPs and (2) in inducing CTL and IFN-g responsein-vivo. Bio-orthogonal in general, refers to any chemical reaction that can occur in the living organism without causing cellular toxicity or interfering with natural biological reactions (38). Furthermore, the azide groups attached to the peptides are metabolically stable and lack any reactivity with natural biological functionalities in the cells as it only reacts with the alkyne groups (39, 40). This new coupling method has shown high selectivity forin vivostudies (41) such as for labeling, imaging, and tracking cells (39, 42). Cu-free click chemistry\nFrontiers in Immunology | www.frontiersin.org 11 May 2019 | Volume 10 | Article 1015\nhas been recently applied for the synthesis of glucoconjugate O-antigen vaccine coupled to CRM197 carrier protein against Salmonella Typhimurium (43).\nIdenti cation of optimal cancer-speci c antigens remains a priority in the eld of cancer immunotherapy. Some scientists favor peptides that are actually presented on the tumor cells using immunopeptidomics and others rely on epitope prediction based on whole exome sequencing. The promising clinical trials conducted so far to test a personalized cancer vaccine have mainly used whole exome sequencing validated by RNA-seq to predict tumor-speci c neoantigens. Immunopeptidomics identi es peptides that are actually presented but requires relatively large amounts of tumor-tissue. By comparison, whole exome sequencing can be performed with minimal cell numbers, but epitopes are only predicted and their presence is not actually physically assessed. In addition, the relative merits of germline vs. mutated epitopes for vaccine design is also disputed. While the former may be conserved in many patients, the latter likely induce less or even no immune tolerance, as they are not expressed in the thymus during early development nor in the periphery other than in tumor cells (14, 15, 44). In our study, to directly compare the di erent approaches, both immunopeptidomics and whole exome sequencing were performed to identify and predict both types of T-cell epitopes. Several T-cell epitopes have been identi ed and prioritized by bioinformatics, as well as by their ability to stimulate TILs from tumor-bearing mice. TILs are highly enriched with speci c T-cells and thus the most relevant T-cell population for anti-tumor T-cell responses. Using these approaches, two sets of peptides, germline and mutated epitopes, were identi ed and displayed on VLPs loaded with CpGs. In recent years, it has become evident that anti-tumor response may be enhanced in the presence of checkpoint inhibitors. Blocking PD-1 vs. depleting Tregs using anti-CD25 mAb was compared. While blocking PD-1 had minimal impact on B16F10 tumor growth, anti-CD25 mAb substantially enhanced protection. Therefor, the developed multi-target VLP-based vaccines were combined with anti-CD25 mAb treatment. The results showed that using germline peptides or mutated or a mixture of both can confer protection against tumor growth in B16F10 melanoma model. Interestingly, mixing both types of epitopes was most promising. This e ect was also shown when calculating the density of CD8C T-cells or CD8C IFN-gC secreting cells in TILs and when assessing the e ect of the vaccines on the myeloid composition of the tumor. Indeed, protection using the MixMTV was as potent as observed with the arti cial model antigen, peptide p33, one of the strongest T-cell epitopes known in mice.\nIt has been shown previously that eliminating large established tumors is challenging even in pre-clinical studies. Kelly et al. has shown that curing a B16F10 melanoma tumor sized 60 80 mm2 is possible when combining four immunotherapeutic agents (31). Here, we have used a more challenging model employing transplanted solid tumors rather than single cell suspension, resulting in tumors with physiological stroma and vascularization. Combining the multi-target VLP-based vaccine with anti-CD25 doubled the lifespan\nof the transplanted mice and changed the immunological milieu of the tumors, which is an impressive result given the model used.\nThe approach of vaccinating with only two neoantigens and combining them with germ-line antigens avoids the need for identifying large numbers of neoantigens that may represent a particular problem in tumors of low mutational burden. A prominent example of this is the aggressive metastatic breast cancer murine cell line 4T1. It has been shown that 4T1 harbored 27 mutations in their expressed genes, however only one mutation was predicted to bind MHC-I H2-Db allele (45). These data are consistent with the fact that human tumors associated with environmental mutagens such as melanoma have more mutations than other cancers (46). Additionally, Keeping the numbers of neoantigens low may also simplify the production of this type of personalized vaccines to some extent, as the nal vaccine formulations would vary less from one patient to the next one, easing the regulatory challenges for producing and releasing these pharmaceutical products for clinical use.\nIn conclusion, this study proposes a novel platform for the development of an immunogenic personalized melanoma vaccine based on VLPs. This vaccine utilizes CTL epitopes predicted and validated by both immunopeptidomics and whole exome sequencing techniques. The peptides were coupled to the highly immunogenic VLPs by Cu-free click chemistry, representing a fast, safe and e cient method of coupling, enabling GMP compliant production for future use in clinical settings. The platform developed here can be used to target potentially any malignant tumor and thus can be applied broadly in cancer medicine.\nETHICS STATEMENT\nAnimal procedures were conducted at the University of Bern, Switzerland, in accordance with the Swiss Animals Act (455.109.1, September 2008, 5th, University of Bern).\nAUTHOR CONTRIBUTIONS\nMM, MV, CR, DS, and MB: design of experiments, acquisition of data, interpretation of data, analysis of data. NT and JM: immunopeptidomics acquisition and data analysis. JM and SS: exome sequencing data analysis. MM, MV, AE-T, GC-M, AG, CR, TK, AK, DS, SD, and MB: writing, revise and revision of manuscript. MM, MV, and CR: technical and material support. MB: study supervision.\nFUNDING\nThis work was supported by the Swiss Cancer League (KFS4132-02-2017) and Qatar National Research Fund (PDRA grant PDRA4-0118-18002).\nACKNOWLEDGMENTS\nThe publication of this article was funded by the Qatar National Library.\nFrontiers in Immunology | www.frontiersin.org 12 May 2019 | Volume 10 | Article 1015\nREFERENCES\n1. Luo C, Shen J. Research progress in advanced melanoma.Cancer Lett. (2017) 397:120 6. doi: 10.1016/j.canlet.2017.03.037 2. Vasquez M, Tenesaca S, Berraondo P. New trends in antitumor vaccines in melanoma.Ann Transl Med. (2017) 5:384. doi: 10.21037/atm.2017.09.09 3. Hu Z, Ott PA, Wu CJ. Towards personalized, tumour-speci c, therapeutic vaccines for cancer.Nat Rev Immunol. (2018) 18:168 82. doi: 10.1038/nri.2017.131 4. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. (2006) 124:783 801. doi: 10.1016/j.cell.2006.02.015 5. Ahi YS, Bangari DS, Mittal SK. Adenoviral vector immunity: itsimplications and circumvention strategies.Curr Gene Ther. (2011) 11:307 20. doi: 10.2174/156652311796150372 6. Hacohen N, Fritsch EF, Carter TA, Lander ES, Wu CJ. Getting personal with neoantigen-based therapeutic cancer vaccines.Cancer Immunol Res. (2013) 1:11 5. doi: 10.1158/2326-6066.CIR-13-0022 7. Lee N, Zakka LR, Mihm MC, Schatton T. Tumour-in ltrating lymphocytes in melanoma prognosis and cancer immunotherapy.Pathology. (2016) 48:177 87. doi: 10.1016/j.pathol.2015.12.006 8. Castle JC, Kreiter S, Diekmann J, Lower M, van de Roemer N, de Graaf J, et al. Exploiting the mutanome for tumor vaccination.Cancer Res. (2012) 72:1081 91. doi: 10.1158/0008-5472.CAN-11-3722 9. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle.Immunity. (2013) 39:1 10. doi: 10.1016/j.immuni.2013.07.012 10. Kruit WH, Suciu S, Dreno B, Mortier L, Robert C, Chiarion-Sileni V, et al. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European organisation for research and treatment of cancer melanoma group in metastatic melanoma.J Clin Oncol. (2013) 31:2413 20. doi: 10.1200/JCO.2012.43.7111 11. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Stratton MR. Signatures of mutational processes in human cancer.Nature. (2013) 500:415 21. doi: 10.1038/nature12477 12. Strasner A, Karin M. Immune in ltration and prostate cancer.F ont Oncol. (2015) 5:128. doi: 10.3389/fonc.2015.00128 13. Martinez-Bosch N, Vinaixa J, Navarro P. Immune evasion in pancreatic cancer: from mechanisms to therapy.Cancers. (2018) 10:6. doi: 10.3390/cancers10010006 14. Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Wu CJ. An immunogenic personal neoantigen vaccine for patients with melanoma.Nature. (2017) 547:217 21. doi: 10.1038/nature22991 15. Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Tureci O. Personalized RNA mutanome vaccines mobilize poly-speci c therapeutic immunity against cancer.Nature. (2017) 547:222 6. doi: 10.1038/nature23003 16. Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti A, et al. Cancer immunotherapy. A dendritic cell vaccine increases th breadth and diversity of melanoma neoantigen-speci c T cells.Science. (2015) 348:803 8. doi: 10.1126/science.aaa3828 17. Speiser DE, Schwarz K, Baumgaertner P, Manolova V, Devevre E, Strry W, et al. Memory and e ector CD8 T-cell responses after nanoparticle vaccination of melanoma patients.J Immunother. (2010) 33:848 58. doi: 10.1097/CJI.0b013e3181f1d614 18. Goldinger SM, Dummer R, Baumgaertner P, Mihic-Probst D, Schwarz K, Hammann-Haenni A, et al. Nano-particle vaccination combined with TLR-7 and 9 ligands triggers memory and e ector CD8(C) T-cell responses in melanoma patients.Eur J Immunol. (2012) 42:3049 61. doi: 10.1002/eji.201142361 19. Kozlovska TM, Cielens I, Vasiljeva I, Strelnikova A, Kazaks A,Dislers A, et al. RNA phage Q beta coat protein as a carrier for foreign epitopes.Intervirology. (1996) 39:9 15. doi: 10.1159/000150469 20. Cielens I, Ose V, Petrovskis I, Strelnikova A, Renhofa R, Kozlovska T, et al. Mutilation of RNA phage Qbeta virus-like particles: from icosahedrons to rods.FEBS Lett. (2000) 482:261 4. doi: 10.1016/S0014-5793(00)02061-5 21. Storni T, Lechner F, Erdmann I, Bachi T, Jegerlehner A, Dumrese T,et al. Critical role for activation of antigen-presenting cells in priming ofcytotoxic T cell responses after vaccination with virus-like particles.J Immunol. (2002) 168:2880 6. doi: 10.4049/jimmunol.168.6.2880\n22. Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. Quant Biol Genom.arXiv:1303.3997 [q-bio.GN] (2013). 23. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. Genome project data processing. The sequence alignment/Map format and SAMtools. Bioinformatics.(2009) 25 2078 9. doi: 10.1093/bioinformatics/ btp352 24. Rimmer A, Phan H, Mathieson I, Iqbal Z, Twigg SR F, Lunter G. Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing applications.Nat Genet. (2014) 46:912 8. doi: 10.1038/ng.3036 25. McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Cunningham F. The ensembl variant e ect predictor.Genome Biol. (2016) 17:122. doi: 10.1186/s13059-016-0974-4 26. Storni T, Bachmann MF. Loading of MHC class I and II presentation pathways by exogenous antigens: a quantitativein vivo comparison.J Immunol. (2004) 172:6129 35. doi: 10.4049/jimmunol.172.10.6129 27. Gomes AC, Flace A, Saudan P, Zabel F, Cabral-Miranda G, Turabi A, et al. Adjusted particle size eliminates the need of linkage of antige and adjuvants for appropriated T cell responses in virus-like particlebased vaccines.Front Immunol. (2017) 8:226. doi: 10.3389/ mmu.2017. 00226 28. Mohsen MO, Gomes AC, Cabral-Miranda G, Krueger CC, Leoratti FM. Delivering adjuvants and antigens in separate nanoparticles eliminates the need of physical linkage for e ective vaccination.J Control Releas.(2017) 251:92 100. doi: 10.1016/j.jconrel.2017.02.031 29. Gooden MJ, de Bock GH, Le ers N, Daemen T, Nijman HW. The prognostic in uence of tumour-in ltrating lymphocytes in cancer: a systematic review with meta-analysis.Br J Cancer. (2011) 105:93 103. doi: 10.1038/bjc.2011.189 30. Haanen JB, Baars A, Gomez R, Weder P, Smits M, de Gruijl T, et al. Melanoma-speci c tumor-in ltrating lymphocytes but not circulating melanoma-speci c T cells may predict survival in resected advancedstage melanoma patients.Cancer Immunol Immunother.(2006) 55:451 8. doi: 10.1007/s00262-005-0018-5 31. Moynihan KD, Opel CF, Szeto GL, Tzeng A, Zhu EF, Irvine DJ. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses.Nat Med. (2016) 22:1402 10. doi: 10.1038/nm.4200 32. Murray AA, Wang C, Fiering S, Steinmetz NF.In situvaccination with cowpea vs tobacco mosaic virus against melanoma.Mol Pharm. (2018) 15:3700 16. doi: 10.1021/acs.molpharmaceut.8b00316 33. Bachmann MF, Jennings GT. Vaccine delivery: a matter of size,geometry, kinetics and molecular patterns.Nat Rev Immunol. (2010) 10:787 96. doi: 10.1038/nri2868 34. Makkouk A, Weiner G J. Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge.Cancer Res. (2015) 75:5 10. doi: 10.1158/0008-5472.CAN-14-2538 35. Schwarz K, Meijerink E, Speiser DE, Tissot AC, Cielens I, Bachm nn MF. E cient homologous prime-boost strategies for T cell vaccination based on virus-like particles.Eur J Immunol. (2005) 35:816 21. doi: 10.1002/eji.200425755 36. Okuyama R, Aruga A, Hatori T, Takeda K, Yamamoto M. Immunological responses to a multi-peptide vaccine targeting cancer-testis antigens and VEGFRs in advanced pancreatic cancer patients.Oncoimmunology. (2013) 2:e27010. doi: 10.4161/onci.27010 37. Donaldson B, Al-Barwani F, Pelham SJ, Young K, Ward VK, Young SL. Multi-target chimaeric VLP as a therapeutic vaccine in a model of colorectal cancer.J Immunother Cancer. (2017) 5:69. doi: 10.1186/s40425017-0270-1 38. Chang PV, Prescher JA, Sletten EM, Baskin JM, Miller IA, Bertozzi CR. Copper-free click chemistry in living animals.Proc Natl Acad Sci USA. (2010) 107:1821 6. doi: 10.1073/pnas.0911116107 39. Baskin JM, Prescher JA, Laughlin ST, Agard NJ, Chang PV, Bertozzi CR. Copper-free click chemistry for dynamicn vivo imaging.Proc Natl Acad Sci USA. (2007) 104:16793 97. doi: 10.1073/pnas.0707090104 40. Mohsen MO, Zha L, Cabral-Miranda G, Bachmann MF. Major ndings and recent advances in virus-like particle (VLP)-based vaccines.S min Immunol. (2017) 34:123 32. doi: 10.1016/j.smim.2017.08.014\nFrontiers in Immunology | www.frontiersin.org 13 May 2019 | Volume 10 | Article 1015\n41. Jewett JC, Bertozzi CR. Cu-free click cycloaddition reactions n chemical biology.Chem Soc Rev. (2010) 39:1272 9. doi: 10.1039/b901970g 42. Yoon HI, Yhee JY, Na JH, Lee S, Lee H, Kim K, et al. Bioorthogonal cpper free click chemistry for labeling and tracking of chondrocytesin vivo. Bioconjug Chem. (2016) 27:927 36. doi: 10.1021/acs.bioconjchem.6b00010 43. Stefanetti G, Saul A, MacLennan CA, Micoli F. Click chemistryapplied to the synthesis of salmonella typhimurium o-antigen glycoconjugate vccine on solid phase with sugar recycling.Bioconjug Chem. (2015) 26:2507 13. doi: 10.1021/acs.bioconjchem.5b00521 44. Kroemer G, Zitvogel L. Can the exome and the immunome converge on the design of e cient cancer vaccines?Oncoimmunology. (2012) 1:579 80. doi: 10.4161/onci.20730 45. Kim K, Skora AD, Li Z, Liu Q, Tam AJ, Zhou S. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells.Proc Natl Acad Sci USA. (2014) 111:11774 9. doi: 10.1073/pnas.1410626111 46. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LAW. Cancer genome landscapes.Science. (2013) 339:1546 58. doi: 10.1126/science.1235122 Con ict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or nancial relationship that could be construed as a potential con ict of interest. Copyright ' 2019 Mohsen, Vogel, Riether, Muller, Salatino, Ternette, Gomes, CabralMiranda, El-Turabi, Ruedl, Kundig, Dermime, Knuth, Speiser and Bachmann. This is an open-access article distributed under the terms of theCreative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction ispermitted which does not comply with these terms.\nFrontiers in Immunology | www.frontiersin.org 14 May 2019 | Volume 10 | Article 1015"
    } ],
    "references" : [ {
      "title" : "Research progress in advanced melanoma",
      "author" : [ "C Luo", "J. Shen" ],
      "venue" : "Cancer Lett  ",
      "citeRegEx" : "1",
      "shortCiteRegEx" : "1",
      "year" : 2017
    }, {
      "title" : "New trends in antitumor vac cines in melanoma.Ann Transl Med",
      "author" : [ "M Vasquez", "S Tenesaca", "P. Berraondo" ],
      "venue" : null,
      "citeRegEx" : "2",
      "shortCiteRegEx" : "2",
      "year" : 2017
    }, {
      "title" : "Towards personalized, tumour-speci c, therapeutic vaccines for cancer",
      "author" : [ "Z Hu", "PA Ott", "CJ. Wu" ],
      "venue" : "Nat Rev Immunol",
      "citeRegEx" : "3",
      "shortCiteRegEx" : "3",
      "year" : 2018
    }, {
      "title" : "Pathogen recognition and innat  e immunity",
      "author" : [ "S Akira", "S Uematsu", "O. Takeuchi" ],
      "venue" : null,
      "citeRegEx" : "4",
      "shortCiteRegEx" : "4",
      "year" : 2006
    }, {
      "title" : "Adenoviral vector immunity: its  implications and circumvention strategies.Curr Gene Ther",
      "author" : [ "YS Ahi", "DS Bangari", "SK. Mittal" ],
      "venue" : null,
      "citeRegEx" : "5",
      "shortCiteRegEx" : "5",
      "year" : 2011
    }, {
      "title" : "Getting per  sonal with neoantigen-based therapeutic cancer vaccines",
      "author" : [ "N Hacohen", "EF Fritsch", "TA Carter", "ES Lander", "CJ. Wu" ],
      "venue" : "Cancer Immunol Res",
      "citeRegEx" : "6",
      "shortCiteRegEx" : "6",
      "year" : 2013
    }, {
      "title" : "Tumour-in ltrating lymphoc  ytes in melanoma prognosis and cancer immunotherapy",
      "author" : [ "N Lee", "LR Zakka", "MC Mihm", "T. Schatton" ],
      "venue" : "Pathology",
      "citeRegEx" : "7",
      "shortCiteRegEx" : "7",
      "year" : 2016
    }, {
      "title" : "Exploiting the mutanome for tumor vaccination",
      "author" : [ "JC Castle", "S Kreiter", "J Diekmann", "M Lower", "N van de Roemer", "J de Graa f" ],
      "venue" : "Cancer Res ",
      "citeRegEx" : "8",
      "shortCiteRegEx" : "8",
      "year" : 2012
    }, {
      "title" : "Oncology meets immunology: the cancer-immunity cycle.Immunity",
      "author" : [ "DS Chen", "I. Mellman" ],
      "venue" : null,
      "citeRegEx" : "9",
      "shortCiteRegEx" : "9",
      "year" : 2013
    }, {
      "title" : "Selection of immunostimulant AS15 for active immunization with MAG  E-A3 protein: results of a randomized phase II study of the European organis ation for research and treatment of cancer melanoma group in metastatic melanoma.J Clin Oncol",
      "author" : [ "WH Kruit", "S Suciu", "B Dreno", "L Mortier", "C Robert", "V Chiarion-Sileni" ],
      "venue" : null,
      "citeRegEx" : "10",
      "shortCiteRegEx" : "10",
      "year" : 2013
    }, {
      "title" : "Signatures of mutational processes in human cancer",
      "author" : [ "LB Alexandrov", "S Nik-Zainal", "DC Wedge", "SA Aparicio", "S Behjati", "MR. Stratton" ],
      "venue" : "Nature",
      "citeRegEx" : "11",
      "shortCiteRegEx" : "11",
      "year" : 2013
    }, {
      "title" : "Immune in ltration and prostate cancer",
      "author" : [ "A Strasner", "M. Karin" ],
      "venue" : "F ont Oncol",
      "citeRegEx" : "12",
      "shortCiteRegEx" : "12",
      "year" : 2015
    }, {
      "title" : "from mechanisms to therapy",
      "author" : [ "N Martinez-Bosch", "J Vinaixa", "cancer Navarro P. Immune evasion in pancreatic" ],
      "venue" : " Cancers .",
      "citeRegEx" : "13",
      "shortCiteRegEx" : null,
      "year" : 2018
    }, {
      "title" : "An immunogenic pe rsonal neoantigen vaccine for patients with melanoma",
      "author" : [ "PA Ott", "Z Hu", "DB Keskin", "SA Shukla", "J Sun", "CJ. Wu" ],
      "venue" : "Nature",
      "citeRegEx" : "14",
      "shortCiteRegEx" : "14",
      "year" : 2017
    }, {
      "title" : "Cancer immunotherapy. A dendritic cell vaccine increases th breadth and diversity of melanoma neoantigen-speci c T cells",
      "author" : [ "BM Carreno", "V Magrini", "M Becker-Hapak", "S Kaabinejadian", "J Hunda l", "A Petti" ],
      "venue" : null,
      "citeRegEx" : "16",
      "shortCiteRegEx" : "16",
      "year" : 2015
    }, {
      "title" : "Memory and e ector CD8 T-cell responses after nanoparticle vaccination of melanoma patients",
      "author" : [ "DE Speiser", "K Schwarz", "P Baumgaertner", "V Manolova", "E Devevre", "W St rry" ],
      "venue" : "J Immunother ",
      "citeRegEx" : "17",
      "shortCiteRegEx" : "17",
      "year" : 2010
    }, {
      "title" : "Nano-particle vaccination combined wit  h TLR-7 and 9 ligands triggers memory and e ector CD8(  C) T-cell responses in melanoma patients",
      "author" : [ "SM Goldinger", "R Dummer", "P Baumgaertner", "D Mihic-Probst", "K Schwarz", "A Hammann-Haenni" ],
      "venue" : "Eur J Immunol",
      "citeRegEx" : "18",
      "shortCiteRegEx" : "18",
      "year" : 2012
    }, {
      "title" : "RNA phage Q beta coat protein as a carrier for foreign epitopes",
      "author" : [ "TM Kozlovska", "I Cielens", "I Vasiljeva", "A Strelnikova", "A Kazaks", "A Dislers" ],
      "venue" : "Intervirology",
      "citeRegEx" : "19",
      "shortCiteRegEx" : "19",
      "year" : 1996
    }, {
      "title" : "Mutilation of RNA phage Qbeta virus-like particles: from icosahedron s to rods.FEBS",
      "author" : [ "I Cielens", "V Ose", "I Petrovskis", "A Strelnikova", "R Renhofa", "T Kozlo vska" ],
      "venue" : null,
      "citeRegEx" : "20",
      "shortCiteRegEx" : "20",
      "year" : 2000
    }, {
      "title" : "Critical role for activation of antigen-presenting cells in priming of  cytotoxic T cell responses after vaccination with virus-like particles",
      "author" : [ "T Storni", "F Lechner", "I Erdmann", "T Bachi", "A Jegerlehner", "T Dumrese" ],
      "venue" : "J Immunol ",
      "citeRegEx" : "21",
      "shortCiteRegEx" : "21",
      "year" : 2002
    }, {
      "title" : "Aligning sequence reads, clone sequences and assembly con  tigs with BWA-MEM",
      "author" : [ "H. Li" ],
      "venue" : "Quant Biol Genom",
      "citeRegEx" : "22",
      "shortCiteRegEx" : "22",
      "year" : 2013
    }, {
      "title" : "Genome project data processing. The sequence alignment/Map format an  d SAMtools",
      "author" : [ "H Li", "B Handsaker", "A Wysoker", "T Fennell", "J Ruan", "N Homer" ],
      "venue" : null,
      "citeRegEx" : "23",
      "shortCiteRegEx" : "23",
      "year" : 2009
    }, {
      "title" : "Integrating mapping-, assembly- and haplotype-based approaches for calli ng variants in clinical sequencing applications",
      "author" : [ "A Rimmer", "H Phan", "I Mathieson", "Z Iqbal", "F Twigg SR", "G. Lunter" ],
      "venue" : null,
      "citeRegEx" : "24",
      "shortCiteRegEx" : "24",
      "year" : 2014
    }, {
      "title" : "The ensembl variant e ect predictor",
      "author" : [ "W McLaren", "L Gil", "SE Hunt", "HS Riat", "GR Ritchie", "F. Cunningham" ],
      "venue" : "Genome Biol",
      "citeRegEx" : "25",
      "shortCiteRegEx" : "25",
      "year" : 2016
    }, {
      "title" : "Loading of MHC class I and II presentatio n pathways by exogenous antigens: a quantitative  in vivo comparison.J Immunol",
      "author" : [ "Storni T", "Bachmann MF" ],
      "venue" : null,
      "citeRegEx" : "26",
      "shortCiteRegEx" : "26",
      "year" : 2004
    }, {
      "title" : "Adjusted particle size eliminates the need of linkage of antig e and adjuvants for appropriated T cell responses in virus-like particlebased vaccines",
      "author" : [ "AC Gomes", "A Flace", "P Saudan", "F Zabel", "G Cabral-Miranda", "A Turabi" ],
      "venue" : "Front Immunol",
      "citeRegEx" : "27",
      "shortCiteRegEx" : "27",
      "year" : 2017
    }, {
      "title" : "Delivering adjuvants and antigens in separate nanoparticles elimina tes the need of physical linkage for e ective vaccination",
      "author" : [ "MO Mohsen", "AC Gomes", "G Cabral-Miranda", "CC Krueger", "FM. Leoratti" ],
      "venue" : "J Control Releas",
      "citeRegEx" : "28",
      "shortCiteRegEx" : "28",
      "year" : 2017
    }, {
      "title" : "a systemati c review with meta-analysis",
      "author" : [ "MJ Gooden", "GH de Bock", "N Le ers", "T Daemen", "cancer Nijman HW. The prognost ic in uence of tumour-in ltrating lymphocytes in" ],
      "venue" : " Br J Cancer  .",
      "citeRegEx" : "29",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Melanoma-speci c tumor-in ltrating lymphocytes but not circula ting melanoma-speci c T cells may predict survival in resected advancedstage melanoma patients",
      "author" : [ "JB Haanen", "A Baars", "R Gomez", "P Weder", "M Smits", "T de Gruijl" ],
      "venue" : "Cancer Immunol Immunother",
      "citeRegEx" : "30",
      "shortCiteRegEx" : "30",
      "year" : 2006
    }, {
      "title" : "E radication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses",
      "author" : [ "KD Moynihan", "CF Opel", "GL Szeto", "A Tzeng", "EF Zhu", "DJ. Irvine" ],
      "venue" : "Nat Med",
      "citeRegEx" : "31",
      "shortCiteRegEx" : "31",
      "year" : 2016
    }, {
      "title" : "In situvaccination with cowpea vs tobacco mosaic virus against melanoma",
      "author" : [ "AA Murray", "C Wang", "S Fiering", "NF. Steinmetz" ],
      "venue" : "Mol Pharm",
      "citeRegEx" : "32",
      "shortCiteRegEx" : "32",
      "year" : 2018
    }, {
      "title" : "a matter of size, geometry, kinetics and molecular patterns",
      "author" : [ "Bachmann MF", "Jennings GT. Vaccine delivery" ],
      "venue" : " Nat Rev Immunol .",
      "citeRegEx" : "33",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "new approaches to an old challenge",
      "author" : [ "Makkouk A", "Weiner G J. Cancer immunotherapy", "breaking immune tolerance" ],
      "venue" : " Cancer Res  .",
      "citeRegEx" : "34",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "E cient homologous prime-boost strategies for T cell vaccinati on based on virus-like particles.Eur",
      "author" : [ "K Schwarz", "E Meijerink", "DE Speiser", "AC Tissot", "I Cielens", "MF. Bach m nn" ],
      "venue" : "J Immunol",
      "citeRegEx" : "35",
      "shortCiteRegEx" : "35",
      "year" : 2005
    }, {
      "title" : "Immunological responses to a multi-peptide vaccine targeting cancer-testis ant  igens and VEGFRs in advanced pancreatic cancer patients",
      "author" : [ "R Okuyama", "A Aruga", "T Hatori", "K Takeda", "M. Yamamoto" ],
      "venue" : "Oncoimmunology",
      "citeRegEx" : "36",
      "shortCiteRegEx" : "36",
      "year" : 2013
    }, {
      "title" : "Multi-target chimaeric VLP as a therapeutic vaccine in a model o  f colorectal cancer",
      "author" : [ "B Donaldson", "F Al-Barwani", "SJ Pelham", "K Young", "VK Ward", "SL. Young" ],
      "venue" : "J Immunother Cancer",
      "citeRegEx" : "37",
      "shortCiteRegEx" : "37",
      "year" : 2017
    }, {
      "title" : "Copper-free click chemistry in living animals",
      "author" : [ "PV Chang", "JA Prescher", "EM Sletten", "JM Baskin", "IA Miller", "CR. Bertoz zi" ],
      "venue" : "Proc Natl Acad Sci USA",
      "citeRegEx" : "38",
      "shortCiteRegEx" : "38",
      "year" : 2010
    }, {
      "title" : "Copper-free click chemistry for dynamic  n vivo",
      "author" : [ "JM Baskin", "JA Prescher", "ST Laughlin", "NJ Agard", "PV Chang", "CR. Berto zzi" ],
      "venue" : "imaging.Proc Natl Acad Sci USA",
      "citeRegEx" : "39",
      "shortCiteRegEx" : "39",
      "year" : 2007
    }, {
      "title" : "Major nding  s and recent advances in virus-like particle (VLP)-based vaccines",
      "author" : [ "MO Mohsen", "L Zha", "G Cabral-Miranda", "MF. Bachmann" ],
      "venue" : "S min Immunol",
      "citeRegEx" : "40",
      "shortCiteRegEx" : "40",
      "year" : 2017
    }, {
      "title" : "Cu-free click cycloaddition reaction  s n chemical biology.Chem",
      "author" : [ "Jewett JC", "Bertozzi CR" ],
      "venue" : "Soc Rev  ",
      "citeRegEx" : "41",
      "shortCiteRegEx" : "41",
      "year" : 2010
    }, {
      "title" : "Bioorthogonal c  pper free click chemistry for labeling and tracking of chondrocytes in vivo",
      "author" : [ "HI Yoon", "JY Yhee", "JH Na", "S Lee", "H Lee", "K Kim" ],
      "venue" : "Bioconjug Chem",
      "citeRegEx" : "42",
      "shortCiteRegEx" : "42",
      "year" : 2016
    }, {
      "title" : "Click chemistry  applied to the synthesis of salmonella typhimurium o-antigen glycoconjugate v  ccine on solid phase with sugar recycling",
      "author" : [ "G Stefanetti", "A Saul", "CA MacLennan", "F. Micoli" ],
      "venue" : "Bioconjug Chem",
      "citeRegEx" : "43",
      "shortCiteRegEx" : "43",
      "year" : 2015
    }, {
      "title" : "Can the exome and the immunome converge on the design of e cient cancer vaccines?  Oncoimmunology",
      "author" : [ "G Kroemer", "L. Zitvogel" ],
      "venue" : null,
      "citeRegEx" : "44",
      "shortCiteRegEx" : "44",
      "year" : 2012
    }, {
      "title" : "Eradication of meta static mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells.Proc",
      "author" : [ "K Kim", "AD Skora", "Z Li", "Q Liu", "AJ Tam", "S. Zhou" ],
      "venue" : "Natl Acad Sci USA",
      "citeRegEx" : "45",
      "shortCiteRegEx" : "45",
      "year" : 2014
    }, {
      "title" : "Cancer genome landscapes",
      "author" : [ "B Vogelstein", "N Papadopoulos", "VE Velculescu", "S Zhou", "LAW. Diaz" ],
      "venue" : null,
      "citeRegEx" : "46",
      "shortCiteRegEx" : "46",
      "year" : 2019
    } ],
    "referenceMentions" : [ {
      "referenceID" : 1,
      "context" : "Therefore, scientists emphasize the need for personalized treatments, in cludi g vaccinations that target neoantigens representing the uniqueness of each patient’s tu mor (2, 3).",
      "startOffset" : 171,
      "endOffset" : 177
    }, {
      "referenceID" : 2,
      "context" : "Therefore, scientists emphasize the need for personalized treatments, in cludi g vaccinations that target neoantigens representing the uniqueness of each patient’s tu mor (2, 3).",
      "startOffset" : 171,
      "endOffset" : 177
    }, {
      "referenceID" : 7,
      "context" : "and that targeting of a single antigen allows tumors to relaps e (8), it is desirable to target multiple antigens ( 3, 9, 10).",
      "startOffset" : 65,
      "endOffset" : 68
    }, {
      "referenceID" : 22,
      "context" : "1, specifying the opti on minFlank D0) (24) to identify SNPs and short indels ( < 50 bp).",
      "startOffset" : 42,
      "endOffset" : 46
    }, {
      "referenceID" : 23,
      "context" : "The 74138 identi ed variants were annotated with standa rd R packages using GENCODE and further investigated with the Variant E ect Predictor Ensembl frame-work (VEP, releas 90) (25).",
      "startOffset" : 178,
      "endOffset" : 182
    }, {
      "referenceID" : 0,
      "context" : "(1) uncoupled Qb-VLP, total 180 monomers, (2) Qb(CpGs)-p33 vaccine using SMPH cross-linker, and (3) Q b(CpGs)-p33 vaccine using",
      "startOffset" : 0,
      "endOffset" : 3
    }, {
      "referenceID" : 1,
      "context" : "(1) uncoupled Qb-VLP, total 180 monomers, (2) Qb(CpGs)-p33 vaccine using SMPH cross-linker, and (3) Q b(CpGs)-p33 vaccine using",
      "startOffset" : 42,
      "endOffset" : 45
    }, {
      "referenceID" : 2,
      "context" : "(1) uncoupled Qb-VLP, total 180 monomers, (2) Qb(CpGs)-p33 vaccine using SMPH cross-linker, and (3) Q b(CpGs)-p33 vaccine using",
      "startOffset" : 96,
      "endOffset" : 99
    }, {
      "referenceID" : 27,
      "context" : "In vitro Validation of Germline and Mutated Epitopes Identi ed by Immunopeptidomics and Predicted by Whole Exome Sequencing Tumor-in ltrating lymphocytes are highly enriched with tum or speci c T-cells and thus are the most relevant T-cell population in this regard (29).",
      "startOffset" : 266,
      "endOffset" : 270
    }, {
      "referenceID" : 0,
      "context" : "The results show that DBCO is superior to SMPH cross-linker in terms of (1) coupling e ciency to Qb-VLPs and (2) in inducing CTL and IFN-g responsein-vivo.",
      "startOffset" : 72,
      "endOffset" : 75
    }, {
      "referenceID" : 1,
      "context" : "The results show that DBCO is superior to SMPH cross-linker in terms of (1) coupling e ciency to Qb-VLPs and (2) in inducing CTL and IFN-g responsein-vivo.",
      "startOffset" : 109,
      "endOffset" : 112
    }, {
      "referenceID" : 43,
      "context" : "It has been shown that 4T1 harbored 27 mutations in their expressed genes, however only one mutation was predicted to bind MHC-I H2-D b allele (45).",
      "startOffset" : 143,
      "endOffset" : 147
    } ],
    "year" : 0,
    "abstractText" : "Citation: Mohsen MO, Vogel M, Riether C, Muller J, Salatino S, Ternette N, Gomes AC, Cabral-Miranda G, El-Turabi A, Ruedl C, Kundig TM, Dermime S, Knuth A, Speiser DE and Bachmann MF (2019) Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Ef cacy of an Instantly Formulated Cancer Nano-Vaccine. Front. Immunol. 10:1015. doi: 10.3389/ mmu.2019.01015 Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Ef cacy of an Instantly Formulated Cancer Nano-Vaccine",
    "creator" : null
  }
}